¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Amino Acid Multiple Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • corrosive acid
    ºÎ½Ä»ê
  • cyanuric acid
    ½Ã¾Æ´©¸£»ê
  • cyclopaldic acid
    ½ÃŬ·ÎÆÈµå»ê
  • cysteic acid
    ½Ã½ºÅ×Àλê
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • chamber acid
    ¿¬½ÇȲ»ê
  • chenodeoxycholic acid
    Äɳ뵥¿Á½ÃÄÝ»ê
  • chitonic acid
    Űſ»ê
  • cholic acid
    ´ãÁó»ê
  • delta-aminolevulinic acid
    µ¨Å¸¾Æ¹Ì³ë·¹ºÒ¸°»ê
  • deoxycholic acid
    µ¥¿Á½ÃÄÝ»ê
  • deoxyribonucleic acid
    µ¥¿Á½Ã¸®º¸ÇÙ»ê, DNA
  • desoxyribonucleic acid
    µ¥¿Á½Ã¸®º¸ÇÙ»ê, DNA
  • dibasic acid
    ÀÌ¿°±â»ê
  • dicarboxylic acid
    µðÄ«¸£º¹½Ç»ê
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • dicarboxylic acid
    µðÄ«¸£º¹½Ç»ê
  • dilute acid
    ¹±Àº»ê
  • essential fatty acid
    ÇʼöÁö¹æ»ê
  • ethylenediamine tetraacetic acid
    ¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • fatty acid
    Áö¹æ»ê
  • fibril acid
    ¼¶À¯»ê
  • fixed acid
    °íÁ¤»ê
  • folic acid
    Æú»ê, ¿±»ê
  • formic acid
    Æ÷¸§»ê, °³¹Ì»ê
  • free acid
    À¯¸®»ê
  • free fatty acid
    À¯¸®Áö¹æ»ê
  • fumaric acid
    Ǫ¸¶¸£»ê
  • gastric acid
    ˤȐ
  • general acid
    ÀϹݻê
  • glacial acetic acid
    ºùÃÊ»ê
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • glacial acetic acid
    ºùÃÊ»ê.
  • glucosidase, alpha-glucosidase(acid maltase)
    -±Û·çÄڽõ¥À̽º, -glucosidase
  • glucuronic acid
    ±Û·çÄí·Ð»ê.
  • glucuronic acid pathway
    ±Û·çÄí·Ð»ê°æ·Î.
  • glutamic acid
    ±Û·çŽ»ê.
  • glutamic acid dehydrogenase
    ±Û·çŽ»êÅ»¼ö¼ÒÈ¿¼Ò, ±Û·çŽ»êµ¥È÷µå·Î°Ô<³ª>Á¦.
  • glutaric acid
    ±Û·çŸ¸£»ê.
  • glyceric acid
    ±Û¸®¼¼¸°»ê(¡­ß«).
  • glyceroboric acid
    ±Û¸®¼¼¸£ºØ»ê
  • glycocholic acid
    ±Û¸®ÄÚÄÝ»ê.
  • glycolic acid
    ±Û¶óÀÌÄÝ»ê
  • gout,uric acid stones
    ¿ä»ê°á¼®
  • guanylic acid deaminase
    ±¸¾Æ´Ò»êµ¥¾Æ¹Ì³ª Á¦.
  • heat and acetic acid test
    °¡¿Â¾Æ¼¼Æ®»ê½ÃÇè (¹ý)(ʥ计­ß«ãËúÐÛö).
  • hemopyrrole carboxylic acid
    Çì¸ðÇÇ·ÑÄ«¸£º¹½Ç»ê.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • multiple sclerosis
    ´Ù¹ß¼º °æÈ­Áõ(ÒýÛ¡àõÌãûùñø).
  • multiple sclerosis
    ´Ù¹ß¼º °æÈ­Áõ(Ìãûùñø)
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ¼º º¸Çà (¡­ÌãûùñøàõÜÆú¼).
  • multiple sclerotic gait
    ´Ù¹ß °æÈ­Áõ¼º º¸Çà (¡­ÌãûùñøàõÜÆú¼).
  • multiple self-healing epithelioma
    ´Ù¹ß¼º ÀÚ¿¬Ä¡À¯ »óÇÇÁ¾
  • multiple serositis
    ´Ù¹ß¼º À帷¿°(¡­í󨝿ú).
  • multiple serositis
    ´Ù¹ß¼º À帷¿°(¡­À帷¿°).
  • multiple sleep latency test ( MSLT )
    ¼ö¸éÀẹ±â ¹Ýº¹°Ë»ç
  • multiple stem line
    ´Ù¹ß¼º °£¼¼Æ÷ÁÖ.
  • multiple stratification
    ´Ù¸éÃþÈ­(ÒýØüöµûù).
  • multiple sweat gland abscess syndrome
    ´Ù¹ß¼º ÇѼ± ³ó¾ç ÁõÈıº
  • multiple trichilemmoma
    ´Ù¹ß¸ðÁ¾
  • multiple trichoepithelioma
    ´Ù¹ß¼º ¸ð³¶»óÇÇÁ¾
  • multiple tube mixer
    ´ÙÁß°ü(Òýñìη)È¥ÇÕ±â
  • multiple vision
    º¹½Ã(ÜÜãÊ), ´Ù½Ã(ÒýãÊ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • "2,5-dihydroxyphenylacetic acid"
    "2,5-ÀÌ(ì£)ÇÏÀ̵å·Ï½ÃÆä´Ò¾Æ¼¼Æ®»ê(ß«) (ÔÒ) homogentisic acid"
  • "1,3-diphosphoglyceric acid"
    "1,3-ÀÌÀλê(ì£×òß«)±Û¸®¼¼¸°»ê(ß«), (ÔÒ) 1,3-bisphosphoglycerate"
  • "2,3-diphosphoglyceric acid"
    "2,3-ÀÌÀλê(ì£×òß«)±Û¸®¼¼¸°»ê(ß«), (ÔÒ) 2,3-bisphosphoglycerate"
  • dipicolinic acid
    µðÇÇÄݸ®´Ñ»ê(ß«)
  • diprotic acid
    À̾çÀÚ »ê(ì£åÕí­ß«)
  • eleostearic acid
    Àϸ®¿À½ºÅ׾Ƹ£»ê(ß«)
  • erythorbic acid
    ¿¡¸®Å丣ºê»ê(ß«)
  • essential fatty acid
    Çʼö Áö¹æ»ê (ù±âÎò·Û¸ß«)
  • ethylenediaminetetraacetic acid
    ¿¡Æ¿·»ÀÌ(ì£)¾Æ¹Î»ç(ÞÌ)¾Æ¼¼Æ®»ê(ß«)
  • ethylenedinitrolotetraacetic acid
    ¿¡Æ¿·»ÀÌ(ì£)³ªÀÌÆ®·Î»ç(ÞÌ)¾Æ¼¼Æ®»ê(ß«)
  • even-numbered fatty acid
    ¦¼ö Áö¹æ»ê(ß«)
  • fatty acid
    Áö¹æ»ê(ò·Û¸ß«)
  • fatty acid activating enzyme
    Áö¹æ»ê Ȱ¼ºÈ­ È¿¼Ò (ò·Û¸ß«üÀàõûùý£áÈ)
  • fatty acid activation
    Áö¹æ»ê Ȱ¼ºÈ­ (ò·Û¸ß«üÀàõûù)
  • fatty acid CoA ligase
    Áö¹æ»ê(ò·Û¸ß«) CoA ¶óÀ̰ÔÀ̽º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
FA false aneurysm; Families Anonymous; Fanconi anemia; far advanced; fatty acid; febrile antigen; femor...
GA Gamblers Anonymous; gastric analysis; gastric antrum; general anesthesia; general angiography; gener...
IAA imidazoleacetic acid; indoleacetic acid; infectious agent, arthritis; insulin autoantibody; Internat...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
TCA T-cell A locus; terminal cancer; tetracyclic antidepressant; total cholic acid; total circulating al...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
IAA indispensable amino acid
NEAA non-essential amino acid
PAS para amino salicylic acid
TAA total amino acid
t-ACPD trans-(+)-1-amino-1,3-cyclopentane dicarboxylic acid
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acid-base compensation
    »ê ¿°±â º¸»ó
  • acid-base indicator
    »ê ¿°±â Áö½Ã¾à
  • acid-fast nonmotile rod
    Ç׻꼺 ºñ¿îµ¿¼º °£±Õ
  • acid-gel application
    °ÖÇü »ê Àû¿ë
  • adenylic acid deaminase
    ¾Æµ¥´Ò»ê Å»¾Æ¹Ì³ë È¿¼Ò
  • aldobionic acid
    ¾Ëµµºñ¿Â»ê
    C11H19O10COOH. ±× ¼ººÐ´çÀÇ Çϳª·Î¼­ ¿ì·Ð»êÀ» ÇÔÀ¯Çϰí ÀÖ´Â ÀÌ´ç·ùÀ̸ç, ¿©·¯ Á¾·ùÀÇ ½Ä¹°¼º °í¹«¿Í ƯÁ¤ÇÑ º´¿øÃ¼ Áß¿¡ Á¸ÀçÇÑ´Ù. Æó·Å±Õ 3ÇüÀÇ Æ¯¼ö ´Ù´ç·ùÀÇ °¡¼öºÐÇØ¿¡ ÀÇÇØ¼­ ¾òÀ» ¼ö ÀÖ´Ù.
  • allokainic acid
    ¾Ë·ÎÄ«ÀÎ »ê
  • alloxyproteic acid
    ¾Ë·Ï½Ã ´Ü¹é»ê
    ¶§¶§·Î ´¢ Áß¿¡ ¹è¼³µÇ´Â À¯È² ÇÔÀ¯ È­ÇÕ¹°.
  • alpha-oxynaphthoic acid
    ¾ËÆÄ-¿Á½Ã³ªÇÁÅä»ê
    °áÁ¤¼ºÀÇ »ê,OHC10H6COOH.°ú°Å¿¡´Â ¹æºÎÁ¦, ¹æÃëÁ¦·Î »ç¿ëµÇ¾ú´Ù.
  • aminoacetic acid
    ¾Æ¹Ì³ë¾Æ¼¼Æ®»ê, ¾Æ¹Ì³ëÃÊ»ê
    ºñÇʼö ¾Æ¹Ì³ë»ê, NH2CH2COOH. ¸¹Àº ´Ü¹éÁúÀÇ ±¸¼º ¼ººÐÀ¸·Î Á¸ÀçÇÑ´Ù. ÇÕ¼ºµÇ°í ÀÖÀ¸¸ç À§ Á¦»êÁ¦¿Í º¸Ãæ½ÄǰÀ¸·Î »ç¿ëµÇ¾îÁø´Ù. ¶ÇÇÑ ¿©·¯ °¡Áö ±ÙÀ°º´ ¹× ¸»ÃÊÇ÷°ü ºÎÀüÁõÀÇ Ä¡·á¿¡µµ »ç¿ëµÈ´Ù.
  • aminobenzoic acid
    ¾Æ¹Ì³ë ¾È½ÄÇâ »ê
    C7H7NO2. ½Ä¹°°ú µ¿¹°Á¶Á÷¿¡ ³Î¸® ºÐÆ÷Çϸç, ºñŸ¹Î B±ºÀÇ ±¸¼º ¼ººÐ¿¡ °ü°èµÈ´Ù. ¼³ÆÄÁ¦ÀÇ Á¤±ÕÀÛ¿ëÀ» ¹«È¿È­½ÃŲ´Ù.
  • arachidonic acid
    ¾Æ¶ó۵·»ê
    1. °íµµÀÇ ºÒÆ÷È­ Çʼö Áö¹æ»ê. CH3
  • arachidonic acid metabolism
    ¾Æ¶ó۵·»ê ´ë»ç¹°Áú
  • arsenic acid
    ºñ»ê
    HAsO©þ. À̰ÍÀÇ ¿°À» ºñ»ê¿°À̶ó°í ºÎ¸£¸ç ÀǾàǰÀ¸·Î ¾²ÀδÙ.
  • arsenoacetic acid
    ¾Æ¸£¼¼³ë¾Æ¼¼Æ®»ê
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á